- Trials with a EudraCT protocol (2)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
2 result(s) found for: Humphrey visual field analyser.
Displaying page 1 of 1.
EudraCT Number: 2020-004917-10 | Sponsor Protocol Number: TIGER | Start Date*: 2023-06-29 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative age-Related macular degeneration (TIGER): a phase 3, pan-European, two-gro... | |||||||||||||
Medical condition: Submacular haemorrhage secondary to exudative age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002895-42 | Sponsor Protocol Number: GITS2013_4.0 | Start Date*: 2013-10-10 | ||||||||||||||||
Sponsor Name:Region Västerbotten | ||||||||||||||||||
Full Title: Glaucoma Intensity Treatment Study – Intensive non-invasive glaucoma treatment vs conventional stepwise treatment – a prospective, randomized phase IV study of disease progression in glaucoma (GITS... | ||||||||||||||||||
Medical condition: Glaucoma, open-angle and PEX glaucoma. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
